Факторы прогноза и отдаленные результаты комбинированного и комплексного лечения меланомы кожи
Диссертация
Число регионарных лимфатических узлов, содержащих метастазы меланомы, является единственной характеристикой, оказывающей значимое влияние на вероятность развития отдаленных метастазов и эффективность комбинированной и комплексной терапии пациентов с III стадией заболевания. Отдаленные метастазы в группе больных с метастазом в один лимфатический узел наблюдали в 57,4% случаев против 82,0% в группе… Читать ещё >
Список литературы
- Анисимов В.В., Вагнер Р. И., Барчук A.C. Меланома кожи: Часть I. -С.Пб.: Наука, -1995.- 152 с.
- Анисимов В.В., Горделадзе A.C., Барчук A.C. и др. Меланома кожи: Атлас клиннко-морфологической диагностики. -СПб: Наука, 1999. 107 с.
- Анисимов В.В. Стандартное обследование пациентов с подозрением на мсланому. Современная клиническая классификация. // Практическая онкология. -2001. —№ 4. —С. 12−22.
- Барчук A.C. Хирургическое лечение меланом. // Практическая онкология. -2001. -№ 4. -С. 30−36.
- Барышников А.Ю. Взаимоотношение опухоли и иммунной системы организма. // Практическая онкология. -2003. -Т. 4. -№ 3. -С. 127−130.
- Березкин Д.П. Метод расчета показателей наблюдаемой и скорректированной выживаемости онкологических больных. // Вопросы онкологии. -1982. -Т. XXVIII. -№ 11. -С. 12 19:
- Березкин Д.П., Айрапетян М. Х., Барсегян B.C. Прогностические факторы, наиболее влияющие на выживаемость меланомой кожи. // Клиника и лечение меланом кожи: Тез. Всесоюзного симпозиума. -JI. -1990. -С. 7−9.
- Боринская С., Хуснутдинова Э. «Этногеномнка: история с географией». //Человек. -2002.-№ 1.-С. 19−30.
- Боринская С. А. Генетическое разнообразие народов. // Природа. -2004. -N 10. -С. 3338.
- Борисова Т.Н. Лучевая терапия в комплексном лечении акральных меланом кожи: автореф. дис.. канд. мед. наук. —Обнинск., 2005. -20 с.
- Вавилов A.M. Опухоли кожи. // Российский медицинский журнал. -2001. -Том 9. № 3−4.-С. 143−145.
- Васильев Ю. М, Социальное поведение нормальных клеток и антисоциальное поведение опухолевых клеток. I. Сигнальные молекулы, вызывающие размножение и гибель клеток. // Соросовский образовательный журнал. -1997. -№ 4. -С. 17−22.
- Васильев Ю.М. Социальное поведение нормальных клеток и антисоциальное поведение опухолевых клеток. II. Клетки строят ткань. // Соросовский образовательный журнал. -1997. -№ 5. -С. 20−25.
- Взаимодействие системы иммунитета и опухоли. Электронный ресурс.: Доступ: http://www.anticancer.net/resan/rbasis.html
- Воробьев A.A., Быков A.C., Караулов A.B. Иммунология и аллергология. -Москва «Практическая медицина», 2006. -288 с.
- Вторая О.М. Предоперационное облучение крупными фракциями в комбинированном и комплексном лечении больных меланомой кожи. Автореф. дисс.. канд. мед. наук. -Обнинск., 2004. -23 с.
- Георгиев Г. П. Как нормальная клетка превращается в раковую. // Соросовский образовательный журнал. -1999. ~№ 4. -С. 17−22.
- Георгиев Г. П. Молекулярно-генетические механизмы прогрессии опухолей. // Соросовский образовательный журнал. -2000. -Т. 6. -№ 11. -С. 2−7(3).
- Гольберт З.В., Романова O.A., Червоная Л. В. О спонтанной регрессии злокачественной меланомы. //Архив патологии. -Л. «Медицина». -1977. -Т.-39. -№б. -С. 36−42.
- Двойрин B.B. Статистическая оценка эффективности лечения онкологических больных методом построения таблиц дожития при клинических испытаниях. Методические рекомендации. -Москва. -1985.-32 с.
- Демидов Л.В. К вопросу о прогнозе при меланоме кожи. // Сборник научных трудов, под редакцией Трапезникова H.H. «Опухоли опорно-двигательного аппарата». Выпуск 8. -Москва, 1981. -С.143−147.
- Демидов Л.В., Алиев М. Д., Мартынова ЕВ. и др. Прогностические факторы в оценке первичной меланомы кожи и их значение для выбора объема оперативного вмешательства. // Материалы VIII Российского онкологического конгресса. -Москва, 2004. -С. 52−54.
- Денисов И.Н. Медицинская диссертация. Современные требования к содержанию и оформлению. -2008. -М. «ГЭОТАР-Медна». -364 с.
- Зарецкая Ю.М. Иммунология и иммуногенетика человека.-М:Триада, 2002.-138 с.
- Иконописов Р., Райчев Р., Киров С., Черноземски И. Пигментные опухоли. -София: Медицина и физкультура, 1977. 268 с.
- Йегер Л. Клиническая иммунология: в 3 т.: Пер. с немец. Портновой А. П., под ред. Петрова Р.В.-М: Медицина, 1990 г.-Т. 1.-С. 101.
- Иегер Л. Клиническая иммунология: в 3 т.: Пер. с немец. Портновой А. П., под ред. Петрова Р.В.-М: Медицина, 1990 г. -Т. 3. -С. 420−421.
- Каракулов Р.К., Кабнев O.K., Пелевина И. И. Кинетика пролиферации клеток в опухолях разного типа и размера. // Медицинская радиология. —1980, -№ 5. — С. 9−13.
- Клименко В. В. Климатическая сенсация. Что нас ожидает в ближайшем и отдаленном будущем? Электронный ресурс.: -2006. Лекция. Доступ: http://www.polit.ru/lectures/2007/02/15/klimetiko.html
- Кондратенко И.В. Клеточные основы иммунного ответа. // Вопросы гематологии онкологии и иммунопатологии в педиатрии. —2003, -Т. 2. —№ 3. -С. 71−78.
- Копнин Б.П. Механизмы действия онкогенов и опухолевых супрессоров. Обзор Электронный ресурс.: Доступ: http://www.nedug.ru/lib/lit/oncol/03janl/15/onco.htm
- Кошевенко Ю.Н. Кожа человека: в 2 т. -М.: Медицина, 2006. -Т. 1. -360 с.
- Кудрявцева Г. Т. Предоперационная лучевая терапия злокачественных опухолей: авторсф. дне.. канд. мед. наук. Обнинск, 1972. — 18 с.
- Кудрявцева Г. Т. Предоперационная лучевая терапия в комплексном лечении злокачественных меланом кожи. // В сб.: Клиника и лечение меланом кожи. Тез. докладов всесоюзного симпозиума. Саратов, 1990. -С. 38−39.
- Кудрявцева Г. Т. Лучевая терапия в комбинированном и комплексном лечении злокачественных меланом кожи: дис. на соискание ученой степени докт. мед. наук. -Обнинск, 1991. —226 с.
- Кудрявцев Д.В., Мардынский Ю. С., Неборак Ю. Т. Кудрявцева Г. Т. Влияние морфологических характеристик опухоли на прогноз у больных с меланомой кожи после комплексной терапии. // Российский онкологический журнал. -2006. -№ 1. -С. 10−14
- Кудрявцев Д.В., Мардынский Ю. С., Кудрявцева Г. Т. Пол, локализация и регионарные метастазы как прогностические факторы при комбинированном и комплексном лечении меланомы кожи. // Вопросы онкологии. -2007. -Т. 53. -№ 2. -С. 170−174.
- Кудрявцев Д.В., Кудрявцева Г. Т. Мардынский Ю.С. Адъювантная химиотерапия как компонент комплексного лечения больных меланомой кожи. // Вопросы онкологии. -2008. —Т. 54. -№ 2. -С. 170−177.
- Ламоткин И.А. Опухоли и опухолеподобные поражения кожи Атлас. -М: Бином. Лаборатория знаний, 2006. -166 с.
- Левит М.Л. Комплексное лечение больных меланомой кожи с предоперационным облучением крупными фракциями: автореф. дисс.. канд. мед. наук —М., 1996. -25 с.
- Лемехов В.Г. Эпидемиология, факторы риска, скрининг мелапомы кожи. // Практическая онкология. -2001. -№ 4(8). -С. 3−11.
- Летягнн В. П Органосохраняющие методы лечения больных первичным раком молочной железы (состояние и перспективы развития). // VIII российский онкологический конгресс. -Москва, 2004.-С. 16−22
- Лойт, А А, Гуляев A.B. Теория лимфогенного метастазирования рака и пролиферации. -СПб.: ЭЛБИ, 2005 -88 с
- Лю М Б., Подобед И. С, Лю Б Н. Роль пероксигенации в инвазивном росте и метастазированин неоплазм // Сб. Научных, трудов «Современные аспекты онкологии и радиологии», посвященных 80-летию академика Балмуханова С. Б. Алматы. -2002. -С. 39−42.
- Малыгин С.Е. Новые сведения о биопсин «сторожевого» лимфатического узла. Сан-антонио 2001: новые решения в хирургии молочной железы. Элекгронный ресурс.: Доступ. http://www.rosoncoweb.ru/hbrar>/sanantonio/01/01 htm
- Машковскпй М.Д. Лекарственные средства: в 2 т. -Минск: Беларусь, 1987. -T-II. -С.377.
- Мейл Д., Брюстоф Дж. Рот Д.Б., Ройт А. Иммунология.: Пер. с англ. М.: Логосфера, 2007 -568 с.
- Минимальные клинические рекомендации Европейского Общества Медицинской Онкологии (ESMO 2003): Пер. с англ. М.: «Издательская группа РОНЦ им. Н Н. Блохина РАМН», 2003.-80 с.
- Мордовцев В.Н., Алчагян Л В., Мордовцева В. В. Правильная диагностика меланоцитарных невусов и оценка риска развития мелапомы кожи. // Гедеон Рихтер в СНГ. -2002 -№ 2(10).
- Невинская М.М. Клиника и лечение^ меланом кожи. —М Медицина, 1970.—183 с.
- Оивин И. А Статистическая обработка результатов экспериментальных исследований // Патологическая физиология и экспериментальная терапия. -1960. -№ 4 -С. 76 85.
- Петраш II. Роль метилирования ДПК в канцерогенезе. Электронный ресурс.: Доступ: www genoterra.ru/news/print/253
- Подъякова Т.С. Лучевое, комбинированное и комплексное лечение больных злокачественными опухолями основных локализаций (клиническая и экономическая эффективность): автораф дисс.. канд мед. наук.-М., 1999.-30 с.
- Пожарисский K.M., Кудайбергенова А. Г., Леенман ЕЕ. Патоморфологическая характеристика и особенности меланомы кожи. Прогностические факторы. // Практическая онкология. -2001.-№ 4.-С. 23−29.
- Попова H.A. Иммунитет против опухолей. Миф или реальность? // Соросовскин образовательный журнал. -2001. -Т. 7-№ 3. -С 12−17.
- Райе Р.Х., Гуляева Л Ф. Биологические эффекты токсических соединений: курс лекций -Новосибирск.: Новосиб гос. ун-т. —2003. — 204 с.
- Ровенский Ю А. Как клетки ориентируются на местности. // Соросовский образовательный журнал —2001 —Т.7.-№ 3.-С 4−11.
- Сергеев Ю.В., Новиков Д. К., Караулов A.B. Сергеев А. Ю. Атопический дерматит: гетерогенность клинических форм и разнообразие механизмов патогенеза. // Иммунопатология, аллергология, инфектология. -2001. -№ 3. -С. 61−73.
- Трапезников H.H., Рабен A.C., Яворский В.В, Титинер Г. Б. Пигментные невусы и новообразования кожи. -Москва «Медицина». —1976. — 177 с.
- Фаллер Д.М., Шилдс Д. Молекулярная биология клетки. М.: Бином-Пресс, 2004. -272с.
- Федоров H.A. Нормальное кроветворение и его регуляция. -М.: Медицина, 1976. 543с.
- Фильченков A.A., Степанов Ю. М., Липкин В. М., Кушлинский Н. Е. Участие системы Fas/Fas- лиганд в регуляции гомеостаза и функционировании клеток иммунной системы. // Аллергология и иммунология. -2002. -Т.З. -С. 24−35.
- Фитцпатрик Д.Е., Элинг Д. Л. Секреты дерматологии. -СПб.: Невский Диалект, 1999.512 с.
- Фрадкин С.З., Залуцкий И. В. Меланома кожи. -Минск.: Беларусь, 2000. 221 с.
- Харкевич Г. Ю., Демидов Л. В., Алиев М. Д. и др. Адъювантная терапия меланомы кожи неблагоприятного прогноза: что предпочесть (Химиотерапия? Интерфероны?) // Материалы VIII Российского онкологического конгресса. — Москва, 2004. -С. 54−57.
- Хэбиф Т.П. Кожные болезни. Диагностика и лечение, ¡-перевод, с английского, под редакцией Кубановой A.A. 2-е издание. -Москва «МЕДпресс-информ». -2007. -672 с.
- Чернух A.M., Фролов Е. П. Кожа. -Москва «Медицина», 1982. -338 с.
- Чпсов В.И., Старинский В. В. Злокачественные новообразования в России в 1999 году: Заболеваемость и смертность. -М. -2000. —238 с.
- Чисов В.И., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в2005 г. (заболеваемость и смертность).-Москва. -2007. —252 с.
- Чисов В.И., Старинский, В.В., Петрова Г. В. Злокачественные новообразования в России в 2006 году. -2008, -М.: ФГУ «МНИОИ им. П. А. Герцена Росмедтехнологии». Москва. -248 с.
- Чисов В.И., Старинский, В.В., Петрова Г. В. Злокачественные новообразования в России в 2007 году. -2009. -М.: ФГУ «МНИОИ им. П. А. Герцена Росмедтехнологии». Москва. -241 с.
- Шанин А.П. Пигментные опухоли. -МедГИз, Ленинградское отделение. -1959. -262 с.
- Шарипов А.Ж. Значение некоторых клинико-морфологических показателей для прогноза при меланоме кожи: автореф. Дис.. канд. мед. наук. -М., 1976. 20 с.
- Яворский В.В. Некоторые вопросы клиники, диагностики и лечения меланомы кожи: автореф. дис.. докт. мед. наук. -Москва, 1975. 30 с.
- Янковский Н.К., Боринская С. А. Наша история, записанная в ДНК. // Природа, -2001. № 6.-с. 10−16.
- Aamdal S., Wolff I., Kaplan S. et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. // Eur J Cancer. -1994. -V. 30A. -N. 8. -P. 1061−4.
- Agarwala S.S., Kirkwood J.M. Interferons in melanoma. // Curr Opin Oncol. -1996. -V. 8. -N. 2.-P. 167−74.
- Agarwala S.S., Kirkwood J.M. Adjuvant therapy of melanoma. // Semin Surg Oncol. -1998. -V. 14. —N. 4. -P. 302−10.
- Agarwala S.S., Ferri W., Gooding W., Kirkwood J.M. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. // Cancer. -1999. -V. 85. -N. 9. -P. 1979−84.
- Agarwala S.S., Kirkwood J.M., Gore M. et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. // J Clin Oncol. -2004. -V. 22. -N. 11. -P. 2101−7.
- Ahmann D.L., Creagan E.T., Hahn R.G. et al. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. // Cancer. -1989. -V. 63. -N. 2. -P. 224−7.
- Albertini J.J., Cruse C.W., Rapaport D. et al. Intraoperative radio-Iympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. II Ann Surg. -1996. —V. 223. -N. 2. -P. 217−24.
- Al-Dewachi H.S., Wright N.A., Appleton D.R., Watson A.J. Cell population kinetics in the mouse jejunal crypt. // Virchows Arch B Cell Pathol. -1975. -V. 18. -N. 3. -P. 225−42.
- Aloia T.A., Grubbs E., Onaitis M. et al. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. // Arch Surg. -2005. -V. 140. -N. 11. -P. 1115−20.
- Amadon Ch. Observations on the malignant melanoma. J. Michigan State Bed. Soc. -1930. -v. 28. -P. 713. Abstr. Amer. J. Cancer. -1931.-15.2. -P. 968.
- Andres P., Cupissol D" Guillot B. et al. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma. // Eur J Dermatol. -1998. -V. 8. -N. 4. -P. 235−9.
- Anderson C.M., Buzaid A.C., Legha S.S. Systemic treatments for advanced cutaneous melanoma. // Oncology (Williston Park). -1995. -V.9. -№ 11 -P. 1149−58.
- Andreola G., Rivoltitni L., Castelli Ch. et all. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing Microvesicles. // J. Exp. Med. -2002. -V. 195. -N. 10. -P. 1303−1316.
- Antoine E.C., Rixe O., Vuillemin E. et al. A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. // Am J Clin Oncol. -1995. -V. 18. -N. 5. — P. 421−4.
- Antoine E.C., Benhammouda A., Bernard A. et al. Salpetriere Hospital experience with biochemotherapy in metastatic melanoma, // Cancer J Sci Am. -1997. -V. 3. -Suppl 1. -P. 16−21.
- Arancia G, Molinari A, Calcabrini A, Meschini S, Cianfriglia M. Intracellular P-glycoprotein in multidrug resistant tumor cells. // Ital J Anat Enibryol. -2001. -V. 106. -N. 2 (Suppl 1). -P. 59−68.
- Ariel I.M. Malignant melanoma of the lower extremity: evaluation of 453 patients. // J Surg Oncol.-1980.-V. 15.-N.2.-P. 147−69.
- Ariel IM. Malignant melanoma of the trunk: a retrospective review of 1128 patients. // Cancer. -1982. -V. 49. -N. 6. -P. 1070−8.
- Armstrong B.K., Kricker A. Cutaneous melanoma. // Cancer Surv. -1994. -V. 19−20. -P. 21 940.
- Ascierto P.A., Palmieri G., Strazzullo M. et al. Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group. // Ann Oncol. -2000. -V. 11. -N. 4. -P. 487−90.
- Ascierto P. A., Scala S., Ottaiano A. Adjuvant treatment of malignant melanoma: Where are we? // Crit Rev Oncol Hematol. -2006. -Jan. -V. 57. -N. 1. -P. 45−52
- Atallah E., Flaherty L. Treatment of metastatic malignant melanoma. // Curr Treat Options Oncol. -2005. -May. -V. 6. -N. 3. -C. 185−93.
- Atkins M.B., Lotze M.T., Dutcher J.P. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of270 patients treated between 1985 and 1993. // J Clin Oncol. -1999.-V. 17.-N. 7.-P. 2105−16.
- Attia P., Phan G.Q., Maker A.V. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. // J Clin Oncol. -2005. -V.23.-N. 25.-P. 6043−53.
- Aviles J. A., Lazaro P., Lecona M. Epidemiology and survival of cutaneous melanoma in Spain: a report of 552 cases (1994−2003). // Rev Clin Esp. -2006. -V. 206. -N. 7. -P. 319−25
- Avril MF, Charpentier P, Margulis A, Guillaume JC. Regression of primary melanoma with metastases. // Cancer. -1992. -V. 15. -V. 69. -N. 6. -P. 1377−81.
- Avril M.F., Aamdal S., Grob J.J. et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. // J Clin Oncol. -2004. -V. 22. -N. 6. -P. 1118−25.
- Bachter D., Balda B.R., Vogt II., Buchels H. Primary therapy of malignant melanomas: sentinel lymphadenectomy. // Int J Dermatol. -1998. -V. 37. -N. 4. -P. 278−82.
- Baekke J., Rytter C., Mouridsen H. et al. A phase 11 trial of recombinant interferon alpha-2b and cisplatin in metastatic melanoma. // Acta Oncol. -2000. -V. 39. -N. 5. -P. 625−8.
- Bafaloukos D., Gogas H., Georgoulias V. et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. // J Clin Oncol. -2002. -V. 20. -N. 2. -P. 420−5.
- Bafaloukos D., Aravantinos G., Fountzilas G. et al. Docetaxel in combination with dacarbazine in patients with advanced melanoma. // Oncology. -2002. -V. 63. -N. 4. -P. 333−7.
- Bafaloukos D., Tsoutsos D., Kalofonos H. et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. // Ann Oncol. -2005. -V. 16. -N. 6. -P. 950−7.
- Bajetta E., Negretti E., Giannotti B. et al. et al. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma. // Am J Clin Oncol. -1990. -V. 13. -N. 5. -P. 405−9.
- Balch C.M. Surgical management of regional lymph nodes in cutaneous melanoma. // J Am Acad Dermatol. -1980. -V. 3. -N. 5. -P. 511−24.
- Balch C.M., Murray D., Presant C., Bartolucci A.A. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. // Surgery. -1984. -V. 95. -N. 4. -P. 454−9
- Balch C.M. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. // J Clin Oncol. -1988. -V. 6. -N. 1. -P. 163−72.
- Balch C.M., Soong S., Smith T. et al. Long-Term Result of a Prospective Surgical Trial Comparing 2 cm vs. 4 cm Excision Margings for 740 Patients with 1−4 mm Melanomas.// Ann. Surg. Oncol. -2001.-V. 8.-N.2.-P. 101−108.
- Balch C.M., Soong S.J., Gershenwald J.E. et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. // J Clin 0ncol.-2001. -V. 19.-N. 16.-P. 3622−34.
- Balch C.M., Buzaid A.C., Soong S.J. et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. // Semin Surg Oncol. -2003. -V. 21. -N. I. -P. 43−52.
- Ballo M.T., Ross M.I., Cormier J.N. et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. // Int J Radiat Oncol Biol Phys. -2006. -V. 64. -N I. -P. 106−13
- Bar M.H., Sznol M., Atkins M.B. et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. // J Clin Oncol. -1990. -V. 8. -N. 7. -P. 1138−47.
- Bassukas I.D., Arai A., Schell H., Hornstein O.P. Growth and cell kinetics of human hair papilla cells in vitro. An autoradiographic and flow cytometric study. // Cell Prolif. -1991. -V. 24. -N. 4. -P. 367−74.
- Batail V. Genetic epidemiology of melanoma.//European Journal of Cancer.-2003.-V. 39.-P. 1341−1347.
- Bear H.D., Neifeld J.P., Kay S. Prognosis of level V malignant melanoma. // Cancer. -1985. -V. 55.-N. 6.-P. 1167−71.
- Beaumont K.A., Newton R.A., Smit D.J. et al. Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. // Hum Mol Genet. -2005. -V. 14. -N. 15.-P. 2145−54.
- Bedikian A.Y., Weiss G.R., Legha S.S. et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. // J Clin Oncol. -1995. -V. 13.-P. 12.-P. 2895−9.
- Berger W., Elbling L., Minai-Pour M. et al. Intrinsic MDR-l gene and P-glycoprotein expression in human melanoma cell lines. // Int J Cancer. -1994. -V. 59. -N. 5. -P. 717−23.
- Berger W., Hauptmann E., Elbling L. et al. Possible role of the multidrug resistance-associated protein (MRP) in cheinoresistance of human melanoma cells. // Int J Cancer. -1997. —V. 71. -N. 1. — P. 108−15.
- Bergmann L. Malignant melanoma prognosis and actual treatment strategies with chemotherapy and biological response modifiers. // Eur J Cancer Clin Oncol. -1989. -V. 25. -Suppl 3. -P. 31−6.
- Bishop E.Z. Melanoma in the negro. // Amer. J. Cancer. -1932. -V. 16. -P. 522.
- Blaheta H.J., Schittek B., Breuninger H. et al. Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. // Int J Cancer. -1998. -V. 79. -N. 4. -P. 318−23.
- Boasberg P.D., Hoon D.S., Piro L.D. et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. // J Invest Dermatol. -2006. -V. 126. -N. 12.-P. 2658−63.
- Braun-Falco O, Landthaler M, Holzel D, Konz B, Schmoeckel C. Therapy and prognosis of malignant melanoma of the skin. // Dtsch Med Wochenschr, -1986. -V. 111. -N. 46. -P. 1750−6.
- BREMIM. Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma. Biological Response Modifiers in Melanoma (BREMIM) Italian Cooperative Group. // Eur J Cancer. -1992. -V. 28A.-N. 10.-P. 1719−20.
- Brenner S, Wolf R. Risk of melanoma after treatment of pigmented lesions with Solcoderm. // Dermatology. -1993. -V. 187. -N. 3. -P. 164−5.
- Bryant P.J., Balderson G.A., Mead P., Egerton W.S. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. // World J Surg. -1995. -V. 19. -N. 3. -P. 363−8.
- Bruley C. Malignant melanoma and hormones. // Contracept Fertil Sex (Paris). -1980. -V. 8. -N. 3.-P. 215−23.
- Bruton J.K., Koeller J.M. Recombinant interleukin-2. // Pharmacotherapy. -1994. -V. 14. -N. 6.-P. 635−56.
- Burrall B., Khatri V. Still debating sentinel lymph node biopsy? // Dermatol Online J. -2001. -V.7.-N.2.-P. 1. Review.
- Buzaid A.C., Grimm E.A., Ali-Osman F. et al. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. // Melanoma Res. -1994. -V. 4. -N. 5. -P. 327−30.
- Buzaid A.C., Tinoco L.A., Jendiroba D. et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. // J Clin Oncol. -1995. -V. 13. -N. 9. -P. 2361−8.
- Byrne M., Van Hazel G., Reynolds P.M. et al. Adjuvant immunotherapy with BCG in stage II malignant melanoma. 11J Surg Oncol. -1983. -V. 23. -N. 2. -P. 114−6.
- Cabanas R.M. An approach for the treatment of penile carcinoma. // Cancer. -1977. -V. 39. -N. 2. -P. 456−66.
- Calabro A., Singletary S.E., Balch C.M. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. // Arch Surg. -1989. -V. 124. -N. 9. -P. 1051−5.
- Callery C, Cochran AJ, Roe DJ et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. //Ann Surg. -1982. -V. 196. -N. 1. -P. 69−75.
- Cameron D.A., Corableet M.C., MacKei R.M. et al. Adjuvant interferon alpha in high risk melanoma. The Scottish study. Br J Cancer. -2001. -V 84. -PI 146−9.
- Carmichael J., Atkinson R.J., Caiman K.C. et al. A multicentre phase II trial of vindesine in malignant melanoma. // Eur J Cancer Clin Oncol. -1982. -V. 18. -N. 12. -P. 1293−5
- Carmo-Pereira J., Costa F.O., Pimentel P., Henriques E. Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. // Cancer Treat Rep. -1980. -V. 64. -N. I. -P. 143−5.
- Cascinelli N., Vaglini M., Nava M. et al. Prognosis of skin melanoma with regional node metastases (stage II), // J Surg Oncol. -1984. -V. 25. -N. 4. -P. 240−7.
- Cascinelli N., Belli F., Santinami M. et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience // Annals of Surgical Oncology. —V. 7. -N. 6. -P. 469 474.
- Cascinelli N., Belli F., Mackie R.M. et al. Effect of long-term adjuvant therapy with interferon-alpa2a in patients with regional node metastases from cutaneous melanoma: A randomized trial. // Lancet. -2001. -V. 358. -P. 866−9.
- Casper E.S., Bajorin D. Phase II trial of carboplatin in patients with advanced melanoma. // Invest New Drugs. -1990. -V. 8. -N. 2. -P. 187−90.
- Castel T, Estape J., Vinolas N. et al. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy. // Dermatologica. -1991. — V. 183.-N. I.-P. 25−30.
- Chan C., O’Day J. Melanoma-associated retinopathy: does autoimmunity prolong survival? // Clin Experiment Ophthalmol. -2001. -V. 29. -N. 4. -P. 235−8.
- Chang A., Hunt M., Parkinson D. R, rt al. Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group. // Am J Clin Oncol. -1993.-V. 16.-N. 2.-P. 152−5.
- Chang E., Rosenberg S.A. Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy. // J Immunother. -2001. -V. 24. -N. 1. -P. 88−90.
- Chang J., Atkinson H., A’Hern R. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. // Eur J Cancer. -1994.-V.30A.-N. 14.-P. 2093−5.
- Chapman P.B., Einhorn L.H., Meyers M.L. et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. // J Clin Oncol. -1999. -V. 17. — N. 9.-P. 2745−51.
- Chua H.L., Serov Y., Brahmi Z. Regulation of FasL expression in natural killer cells. // Hum. Immunol. -2004. -V. 65. -N. 4. -P. 317−27.
- Clark W.H. Jr., Ainsworth A.M., Bernandino E.A. et al. The histogenesis and biologic behavior of primary melanomas of the skin // Cancer Res. -1969. -V. 29. -N. 3. -P. 705−726.
- Clark W.H. Jr., Ainsworth A.M., Bernardino E.A. et al. The developmental biology of primary human malignant melanomas. // Scmin Oncol. -1975. -V. 2. -N. 2. -P. 83−103.
- Clark W.H. Jr., Elder D.E. Guerry D.G., IV et al. Model predicting survival in stage I melanoma based on tumor progression. // J. Nat. Cancer Inst. -1989. -Vol. 81. -P. 1893−1904,
- Coates A., Railings M., Hersey P., Swanson C. Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. HI Interferon Res. -1986. -V. 6. -N. 1. -P. 1−4.
- Cocconi G., Bella M., Calnbresi F. et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. // N Engl J Med. -1992. -V. 327. -N. 8. -P. 516−23.
- Cochran A.J. The incidence of melanocytes in normal human skin. // J. Invest. Derm. —1970. -V. 55.-P. 65−70.
- Cochran A.J., Wen D.R., Morton D.L. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. // Am J Surg Pathol. -1988. -V. 12. -N. 8.-P. 612−8.
- Cochran A.J., Lana A.M., Wen D.R. Histomorphometry in the assessment of prognosis in stage II malignant melanoma. // Am J Surg Pathol. -1989. -V. 13. -N. 7. -P. 600−4.
- Cohen M.H., Schour L., Felix E.L. et al. Staging laparotomy in the treatment of metastatic melanoma of the lower extremities. // Ann Surg. -1975. -V. 182. -N. 6. -P. 710−4.
- Cohen Y., Haim S., Bartal A., Robinson E. Vitiligo associated with BCG-methanol extraction residue in malignant melanoma. Report of a case. II Dermatologica. -1979. -V. 158. -N. l.-P. 8−12.
- Coit D.G., Brennan M.F. Extent of lymph node dissection in melanoma of the trunk or lower extremity. // Arch Surg. -1989. -V. 124. -N. 2. -P. 162−6.
- Costanzi J.J., Al-Sarraf M., Groppe C. et al. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study. // Med Pcdiatr Oncol. -1982. —V. 10. -N. 3. -P. 251−8
- Creagan E.T., Ingle J.N., Green S.J. rt al. Phase II study of tamoxifen in patients with disseminated malignant melanoma. // Cancer Treat Rep. -1980. -V. 64. -N. 2−3. -P. 199−201.
- Creagan E.T., Ingle J.N., Ahmann D.L., Green S.J. Phase II study of high-dose tamoxifen (NSC-180 973) in patients with disseminated malignant melanoma. // Cancer. -1982. -V. 49. -N. 7. -P. 1353−4.
- Creagan E.T., Ingle J.N., Schutt A.J., Schaid D.J. A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. // Am J Clin Oncol. -1989. -V. 12. —N. 2. -P. 152−5.
- Creagan E.T. Regional and systemic strategies for metastatic malignant melanoma. // Mayo Clin Proc. -1989. -V. 64. -N. 7. -P. 852−60.
- Creagan E.T., Schaid D.J., Ahmann D.L., Frytak S. Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations. // J Invest Dermatol. -1990. -V. 95. -N. 60 Suppl. -P. 188−192.
- Creagan E.T., Dalton R.J., Ahmann D.L. et al. Randomized surgical adjuvant clinical trial or recombinant interferon-alfa2a in selected patients with malignant melanoma. // J Clin Oncol. -1995. -V. 13. -P. 2776−83.
- Cree I.A. Cell cycle and melanoma—two different tumours from the same cell type. // J Pathol. -2000. -V. 191. -N. 2. -P. 112−4.
- Creech O. Jr., Krementz E., Ryan R. Chemotherapy of melanoma of the extremities by isolated perfusion. // Cancer Chemother Rep. -1962. -V. 16. -P. 579−81.
- Crowell E.B. Jr., Higa G.M. The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen. // W V Med J. -1993. -V. 89. -N. 6. -P. 233−5.
- Crowley NJ, Seigler HF. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. // Cancer. -1990. -V. 66. -N. 12. -P. 2522−7.
- Dale P. S., Foshag L.J., Wanek L.A., Morton D.L. Metastasis of primary melanoma to two separate lymph node basins: prognostic significance. // Ann Surg Oncol. -1997. -V. 4.-N. l.-P. 13−8.
- Daneshpazhooh M., Shokoohi A., Dadban A., Raafat J. The course of melanoma-associated vitiligo: report of a case. // Melanoma Res. -2006. -V. 16. -N. 4. -P. 371−3.
- Danson S., Lorigan P., Arance A. et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. // J Clin Oncol. -2003.-V. 21.-N. 13.-P. 2551−7.
- Daponte A., Ascierto P.A., Gravina A. et al. Temozolomide and cisplatin in avdanced malignant melanoma. // Anticancer Res. -2005. -V. 25. -N. 2B. -P. 1441−7.
- Day C.L., Sober A. J., Kopf A.W. A prognostic model for clinical stage I melanoma of the upper extremity: the importance of anatomic subsites in predicting recurrent disease. // Ami. Surg. -1981. -Vol. 193.-P. 436−440.
- Delia Torre G., Pasini B., Frigerio S. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. // Br J Cancer. -2001. -V. 85. -N. 6. -P. 836−44.
- De Marco F., Foppoli C., Coccia R. Ectopic deposition of melanin pigments as detoxifying mechanism: a paradigm for basal nuclei pigmentation. // Biochem Biophys Res Commun. -2004. -V. 314. -N. 2.-P. 631−7.
- Demunter A., Stas M., Degreef H. Analysis of N and K ras mutations in the distinctive tumor progression phases of melanoma. // J Invest Dermatol. -2001. -V. 117. -N. 6. -P. 1483−9.
- Denninghoff V.C., Kahn A.G., Falco J. et al. Sentinel lymph node: detection of micrometastases of melanoma in a molecular study. // Mol Diagn. -2004. -V. 8. -N. 4. -P. 253−8.
- Desai PB, Duan J, Sridhar R, Damle BD. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. // Methods Find Exp Clin Pharmacol. -1997. -V. 19.-N. 4.-P. 231−9.
- Dhingra K., Papadopoulos N., Lippman S. et al. Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma. // Invest New Drags. -1993. -V. 11. -N. 1. -P. 39−43.
- Dias Moreira R., Altino de Almeida S., Maliska Guimaraes CM. et al. Sentinel node identification by scintigraphic methods in cutaneous melanoma. // J Exp Clin Cancer Res. -2005. -V. 24. -N. 2. -P. 181−5.
- Di Lauro V., Scalone S., La Mura N. et al. Combined chemoimmunotherapy of metastatic melanoma: a single institution experience. // Melanoma Res. -2005. -V. 15. -N. 3. -P. 209−12.
- Dorval T., Mathiot C., Chosidow O. et al. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters. // Biotechnol Ther. -1992. -V. 3. -N. 1−2. -P. 63−79.
- Dorval T., Fridman W.H., Mathiot C. et al. Treatment of metastatic malignant melanoma with interleukin-2. // Bull Cancer. -1992. -V. 79. -N. 8. -P. 781−7.
- Douglas R. Green & Thomas A. Ferguson. The role of fas ligand in immune privilege. // Nature Reviews Molecular Cell Biology. -2001. -V. 2. -N. 12.
- Dreau D., Foster M., Hogg M. et al. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma, // Oncol Res. -2000. -V. 12. -N. 5. -P. 24 151.
- Drepper H., Biess B., Hofherr B. et al. The prognosis of patients with stage III melanoma. Prospective long-term study of 286 patients of the Fachklinik Hornheide. // Cancer. -1993. -V. 71. -N. 4. -P. 1239−46.
- Du bra P, Ilchyshyn A. Prolonged survival in metastatic malignant melanoma associated with vitiligo. // Clin Exp Dermatol. -1991. -V. 16. -N. 4. -P. 303−5.
- Dunne B.M., McNamara M., Clynes M. et al. MDR1 expression is associated with adverse survival in melanoma of the uveal tract. // Hum Pathol. -1998. -V. 29. -N. 6. -P. 594−8.
- Eggermont A.M. European approach to the treatment of malignant melanoma. // Curr Opin Oncol. -2002. -V. 14. -N. 2. -P. 205−11.
- Egyhazi S., Margison G.P., Hansson J., Ringborg U. Immunohistochemical examination of the expression of 06-methylguanine-DNA methyltransferase in human melanoma metastases. // Eur J Cancer. -1997. -V. 33. -N. 1. -P. 129−34.
- Einzig A.I., Hochster H., Wiernik P.H. et al. A phase II study of taxol in patients with malignant melanoma. // Invest New Drugs. -1991. -V. 9. -N. 1. -P. 59−64.
- Einzig A.I., Schuchter L.M., Recio A. et al. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. // Med Oncol. -1996. -V. 13. -N. 2.-P. 111−7.
- Eilerhorst J.A., Bedikian A., Ring S. et al. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. // Oncol Rep. -1999. -V. 6. -N. 5. -P. 1097−9.
- Ellerhorst J.A., Bedikian A.Y., Smith T.M. et al. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. // Anticancer Drugs. -2002. -V. 13. -N. 2. -P. 169−72.
- Epstein W. L., Sangebeil R. et al. //J. A.M. A. -1973. -V. 225. -P. 373−377.
- Eton O., Legha S.S., Bedikian A.Y. et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. // J Clin Oncol. -2002. -V. 20. -N. 8. -P. 2045−52.
- Evans L.M., Casper E.S., Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. // Cancer Treat Rep. -1987. -V. 71. -N. 2. -P. 171−2
- Falkson C.I., Falkson G., Falkson H.C. Phase II trial of fotemustine in patients with metastatic malignant melanoma. // Invest New Drugs. -1994. -V. 12. ~N. 3. -P. 251−4.
- Feind C., Herter F., Markowitz A. Improvements in isolation head perfusion. // Am J Surg. -1963.-V. 106.-P. 777−82.
- Feliu J., Gonzalez Baron M., Chacon J.I. et al. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen. // Cancer Chemother Pharmacol. -1996. -V. 38. -N. 2. -P. 191−4.
- Feng H., Zeng Y., Graner M.W. et al. Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway. //J Biomed Biotechnol. -2004. -N. 1. -P. 41−51.
- Feun L.G., Savaraj N., Hurley J., Marini A. Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma. // Cancer Invest. -2002. -V. 20. -N. 3. -P. 357−61.
- Feun L., Marini A., Moffat F. et al. Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma. // Cancer Invest. -2005. -V. 23. -N. 1. -P. 3−8.
- Fiedler H., Hetschko I., Wohlrab W. et al. Results of a randomized polychemotherapy study in malignant melanoma. // Hautarzt. -1990. -V. 41. -N. 7. -P. 369−74.
- Fierlbeck G., Ulmer A., Schreiner T. et al. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. // J Interferon Cytokine Res. -1996. -V. 16. -N. 10. -P. 777−81.
- Fierro M.T., Bertero M., Novelli M. et al. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. // Melanoma Res. -1993. -V. 3. -N. 2. -P. 127−31.
- Fischer B., Knop J., Enk A.H. Experiences with therapy of stage IV metastatic malignant melanoma with «Legha Protocol» polychemoimmunotherapy. // Hautarzt. -2002. -V. 53. -N. 6. -P. 393−9.
- Flaherty L.E., Liu P.Y., Mitchell M.S. et al. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921). // Am J Clin Oncol. -1996. -V. 19.-N. 2.-P. 108−13.
- Fletcher W.S., Daniels D.S., Sondak V.K. et al. Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study. // Am J Clin Oncol. -1993. -V. 16. -N. 4. -P. 359−62.
- Forrest J.B., Forrest H.J. Case report: malignant melanoma arising during drug therapy for vitiligo. //J Surg Oncol. -1980. -V. 13. -N. 4. -P. 337−40.
- Fortner J.G., Rosen P.P., Maclean B.J. Selective use of wide excision with elective lymph node dissection for malignant melanoma. // Pathol Annu. -1985. -V. 20. -N. 1. -P. 239−46.
- Franke W., Neumann N.J., Ruzicka T., Schulte K.W. Adjuvant therapy of malignant melanoma. // Schweiz Rundsch Med Prax. -2001. -V. 90. -N. 8. -P. 301−6.
- Franzini M" Corti A., Lorenzini E. et al. Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells. // Eur J Cancer. -2006. -V. 42. -N. 15. -P. 262 330.
- Frick S., Lischner S., Rosien F. et al. Teniozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis. // Hautarzt. -2002. -V. 53. -N. 10. -P. 659−65.
- Friedland A.M., Weinstein G.D. Cell proliferation in human cutaneous squamous cell carcinoma. // J Natl Cancer Inst. -1977. -V. 59. -N. 1. -P. 3−6.
- Frost P. J., Butterfield L.H., Dissette V.B.et al. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. J Immunol. -2001. -V. 166. -N. 5. -P. 3564−73.
- Gajewski T.F., Sosman J., Gerson S.L.et al. Phase II trial of the 06-alkylguanine DNA alkyltransferase inhibitor 06-benzylguanine and l, 3-bis (2-chioroethyl)-l-nitrosourea in advanced melanoma. // Clin Cancer Res. -2005. -V. 11. -N. 2. -P. 7861−5.
- Gallagher W.M., Bergin O.E., Rafferty M. et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. // Carcinogenesis. -2005. -V. 26. -N. 11. -P. 1856−67.
- Garbe C., Guenther-Eymann K., Stadler R., Orfanos C.E. Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage lib. // Hautarzt. -1988. -V. 39. -N. 4. -p. 205−12.
- Garbe C., Stadler R., Orfanos C.E. Local recurrence and metastasis of thin malignant melanomas (less than or equal to 1mm). // Hautarzt. -1989. -V. 40. -N. 6. -P. 337−43.
- Garbe C., Zouboulis C.C., Kruger S. et al. Combination of interferon-alpha with cytostatic drugs: a potentially successful therapeutic approach in metastatic melanoma. // Hautarzt. -1992. -V. 43. -N. 1. -P. 4−10.
- Garbe C. Chemotherapy and chemoiinmunothernpy in disseminated malignant melanoma. // Melanoma Res. -1993. -V. 3. -N. 4. -P. 291−9.
- Gelmann E.P. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. // Semin Oncol. -1997. -V. 24. -N. 1 Suppl 1. -P. S1−65-S1−70.
- Gerard B., Aamdal S., Lee S.M. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents—dacarbazine and fotemustine—in patients with melanoma. // Eur J Cancer. -1993. -V. 29A. -N. 5. -P. 711−9.
- Gerber S.A., Moran J.P., Frelinger J.G. et al. Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. // Br J Cancer. 2003. -V. 88. -N. 9. -P. 1453−61.
- Gershenwald J.E., Colome M.I., Lee J.E. et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. // J Clin Oncol. -1998. -V. 16. -N. 6. -P. 2253−60.
- Gilhar A., Ullmann Y., Karry R. et al. Aging of Human Epidermis: Reversal of Aging Changes Correlates With Reversal of Keratinocyte Fas Expression and Apoptosis. // J. Gerontol. A. Biol. Sci. Med. Sci. -2004. -V.59. -N. 5. -P. 411−415.
- Gipponi M., Solari N., Lionetto R. et al. The prognostic role of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma: experience of the Genoa group. // Eur J Surg Oncol. -2005. -V. 31. -N. 10-P. 1191−7.
- Glover D., Ibrahim J., Kirkwood J. et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (El686). // Melanoma Res. -2003. -V. 13. -N. 6. -P. 619−26.
- Gogas H., Paterakis G., Frangia K. et al. Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B. // Am J Clin Oncol. -2002. -V. 25. -N. 6. -P. 591−6.
- Gonzalez Cao M., Malvehy J., Marti R. et al. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. // Melanoma Res. -2006. -V. 16. -N. 1. -P. 59−64.
- Gottlieb Dj., Micklethwaite K., Bradstock K" Li Y.C. Rapid expansion of tumor-reactive cells from HLA-matched siblings for adoptive immunotherapy of melanoma. // Cytotherapy. -2007. -V. 9. -N. 2.-P. 133−43.
- Gould E.A., Winship T" Philbin P.H., Kerr H.H. Observations on a «Sentinel Node» in cancer of the parotid.// Cancer. 1960. -Vol. 13. — P. 77−78.
- Graeven U., Rodeck U., Karpinski S. et al. Expression patterns of placenta growth factor in human melanocytic cell lines. // J Invest Dermatol. -2000. -V. 115. -N. 1. -P. 118−23.
- Green M.D., MacKay I.R., Buckley J.C., Coates A.S. The survival of patients with malignant melanoma receiving BCG with or without chemotherapy. // Aust N Z J Surg. -1979. -V. 49. -N. 3. -P. 335−9.
- Grob J. J., Dreno B., Chastang C. et al. Randomized trial of interferon a-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet.-1998.-V. 351.-P. 1905−10.
- Grulich A., Bataille V., Swerdlow A et al. Naevi and pigmentary characteristic for melanoma in high risk population: a case control study in New South Wales. // Int. J. Cancer. -1996. -V. 67. -P. 485−491.
- Grunhagen D.J., Eggermont A.M., van Geel A.N. et al. Prognostic factors after cervical lymph node dissection for cutaneous melanoma metastases. // Melanoma Res. -2005. -V. 15. -N. 3. -P. 179−84.
- Hakansson A., Gustafsson B., Krysander L., Hakansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. // J Interferon Cytokine Res. -1998. -V. 18. -N. 1. -P. 33−9.
- Hakansson A., Gustafsson B., Krysander L. et al. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. // Br J Cancer. -2001. -V. 85. -N. 12. -P. 1871−7.
- Hakansson A., Hakansson L., Gustafsson B. et al. Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28. II Cancer Immunol Immunother. -2002. -V. 51. -N. 9. -P. 499−504.
- Hakansson A., Gustafsson B., Abdiu A. et al. Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy. // Cancer Immunol Immunother. -2003. -V. 52. -N. 4. -P. 249−54.
- Hakansson A., Hakansson L., Gustafsson B. et al. On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation. // Melanoma Res. -2003. -V. 13. -N. 4. -P. 401−7.
- Handley W.S. The peimeation theory of dissemination in modern operative surgery. Ed. by Turner, 3 ed., London -New York. -1943. -Ch. XI. Principles of operative treatment of malignant disease. -P. 552−555.
- Harrist T.J., Rigel D.S., Day C.L. Jr. et al. «Microscopic satellites» are more highly associated with regional lymph node metastases than is primary melanoma thickness. // Cancer. -1984. -V. 53. -N. 10. -P. 2183−7.
- Hashemi J., Platz A., Ueno T. et al. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. // Cancer Res. -2000. -V. 60. -N. 24. -P. 6864−7.
- Heere-Ress E., Thallinger C., Lucas T. et al. Bcl-X (L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. // Int J Cancer. -2002. -V. 99. -N. l.-P. 29−34.
- Hellebrekers D.M., Jair K.W., Vire E. et al. Angiostatic activity of DNA methyltransferase inhibitors. // Mol Cancer Ther. -2006. -V. 5. -N. 2. -P. 467−75.
- Heller R., Becker J., Wasselle J. et al. Detection of occult lymph node metastases in malignant melanoma. //Department of Surgery, University of South Florida, Tampa. // Ann Plast Surg. -1992. -V.28.-N. l.-P. 74−7.
- Hennessy A., Oh C., Diffey B. Eumelanin and pheomelanin concentrations in human epidermis before and after UVB irradiation. // Pigment Cell Res. -2005. -V. 18. -N. 3. -V. 220−3.
- Hernberg M., Turunen J.P., Muhonen T., Pyrhonen S. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. // J Immunother. -1997. -V. 20. -N. 6. -P. 488−95.
- Hernberg M.M., Hahka-Kemppinen M.H., Pyrhonen S.O. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma. // Melanoma Res. -2004. -V. 14. -N. 6. -P. 493−500.
- Hill G.J. 2nd., Moss S.E., Golomb F.M. et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45 388) Surgical Adjuvant Study COG PROTOCOL 7040. // Cancer. -1981. -V. 47. -N. 11. -P. 2556−62.
- Hirota T. Ultrastructural study of anti-tumor effects of tamoxifen in two malignant melanoma patients. // J Dermatol. -1997. -V. 24. -N. 7. -P. 441−50.
- Hochster H., Strawderman M.H., Harris J.E. et al. Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (El 687). // Anticancer Drugs. -1999. -V. 10. -N. 2. -P. 245−8.
- Hodi F.S., Soiffer R.J., Clark J. et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. //Am J Clin Oncol. -2002. -V. 25. -N. 3. -P. 283−6.
- Hogg D., Brill H., Liu L., Monzon J. Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma. // J Cutan Med Surg. -1998. -V. 2. -N. 3. -P. 172−9.
- Holmes E.C., Clark W., Morton D.L. et al. Regional lymph node metastases and the level of invasion of primary melanoma. // Cancer. -1976. -V. 37. -N. I. -P. 199−201.
- Hotz G., Hagedorn M., Petres J., Wiebelt H. Preventive lymphadenectomy in cutaneous malignant melanomas. A matched pair study. // Hautarzt. -1986. -V. 37. -N. 10. -P. 554−9.
- Hundeiker M., Lippold A., Peters A. Metastatic melanoma of low Breslow thickness. // Hautarzt. -1997. -V. 48. -N. 3. -P. 171−4.
- Hwu W.J., Krown S.E., Menell J.H. et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. // J Clin Oncol. -2003. -V. 21. -N. 17. -P. 3351−6.
- IIwu W.J., Lis E., Menell J.H. et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. // Cancer. -2005. -V. 103. -N. 12. -P. 2590−7.
- Ichihashi N., Kitajima Y. Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells. // Br J Dermatol. -2001. -V. 144. -N. 4. -P. 745−50.
- Inazava J., Itoh N., Abe T., Nagata S. Assignment the Human Fas antigen gene (Fas) to 10q24.1. Genomics-1992.-V. 14.-P. 821−822.
- Inman J.L., Russell G.B., Savage P., Levine E.A. Low-dose adjuvant interferon for stage III malignant melanoma. // Am Surg. -2003. -V. 69. -N. 9 -N. 2. -P. 127−30.
- International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP. Statement on steroidal oral contraceptives. IPPF Med Bull. -1981. -V. 15. -N. 6. -P. 3−5.
- Ito S., Wakamatsu K. Quantitative analysis of eumelanin and pheomelanin in humans, mice, and other animals: a comparative review. // Pigment Cell Res. -2003. -V. 16. -N. 5. -P. 523−31.
- Itoh K., Hayakawa K., Salmeron M.A.et al. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. // Cancer Immunol Immunother. -1991. -V. 33. -N. 4. -P. 238−46.
- James W. Jakub, Solange Pendas, Douglas S. Reintgen Current Status of Sentinel Lymph Node Mapping and Biopsy: Facts and Controversies II The Oncologist. -2003. -V. 8. -N. 1. -P. 59−68.
- Jimenez R.E., Panageas K., Busam K.J., Brady M.S. Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma. // J Clin Oncol. -2005. -V. 23. -N. 3. -P. 518−24.
- Joensuu H., Nordman E., Toivanen A. Long-term effect of levamisole on the immune functions in melanoma patients. // Strahlenther Onkol. -1986. -V. 162. -N. 12. -P. 753−6.
- Joseph E., Brobeil A., Glass F. et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. // Ann Surg Oncol. -1998. -V. 5. -N. 2. -P. 119−25.
- Jovic V., Konjevic G., Radulovic S. et al. Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma. // Tumori. -2001. -V. 87. -N. 5. -P. 324−9.
- Jungnelius U., Ringborg U., Aamdal S. et al. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. // Eur J Cancer. -1998. -V. 34. —N. 9. —P. 1368−74.
- Kadekaro A.L., Kavanagh R.J., Wakamatsu K. et al. Cutaneous photobiology. The melanocyte vs. the sun: who will win the final round? // Pigment Cell Res. -2003. -V. 16. -N- 5. -P. 434−47.
- Kanter-Lewensohn L., Girnita L., Girnita A. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. // Mol Cell Endocrinol.-2000.-V. 165.-N. 1−2.-P. 131−7.
- Karakousis C.P., Carlson M. High-dose methotrexate in malignant melanoma. // Cancer Treat Rep. -1979. -V. 63. -N. 8. -P. 1405−7.
- Karakousis C.P., Stahl L., Moore R., Holyoke E.D. Lymph node dissection in malignant melanoma. // J Surg Oncol. -1980. -V. 13.-N. 3. -P. 245−52.
- Karakousis C.P., Lopez R.E., Bhakoo H.S. et al. Estrogen and progesterone receptors and tamoxifen in malignant melanoma. // Cancer Treat Rep. -1980. -V. 64. -N. 6−7. -P. 819−27.
- Karakousis C.P., Seddiq M.K., Moore R. Prognostic value of lymph node dissection in malignant melanoma. II Arch Surg. -1980. -V. 115. -N. 6. -P. 719−22.
- Karakousis C.P., Driscoll D.L., Rose B., Walsh D.L. Groin dissection in malignant melanoma. II Ann Surg Oncol. -1994. -V. 1. -N. 4. -P. 271−7.
- Karakousis C.P., Driscoll D.L. Positive deep nodes in the groin and survival in malignant melanoma. // Am J Surg. -1996. -V. 171. -N. 4. -P. 421−2.
- Karakousis C.P., Balch C.M., Urist M.M. et al. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Annals of Surgical Oncology. 1996. -V. 3. -N. 5. -P. 446−452.
- Karg C., Garbe C., Orfanos C.E. Chemotherapy of malignant melanoma—current status. // Hautarzt. -1990. -V. 41. -N. 2. -P. 56−65.
- Kavanagh D., Hill A.D., Djikstra B. et al. Adjuvant therapies in the treatment of stage II and III malignant melanoma. // Surgeon. -2005. -V. 3. -N. 4. -P. 245−56.
- Keltner J.L., Thirkill C.E., Yip P.T. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. // J Neuroophthalmol. -2001. -V. 21. -N. 3. -P. 173−87.
- Kemp E.H., Waterman E.A., Weetman A.P. // Autoimmune aspects of vitiligo. Autoimmunity. -2001. -V. 34. -N. 1. -P. 65−77.
- Khayat D., Bore. C., Tourani J.M. et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. // J Clin Oncol. -1993. -V. 11. -N. 11. -P. 217 380.
- Kim E.M., Sivanandham M., Stavropoulos C.I. et al. Overview analysis of adjuvant therapies for melanoma-a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials. // Surg Oncol.-2001.-V. 10.-N. 1−2.-P. 53−9.
- Kirkwood J.M., Strawderman M.H., Ernstoff M.S. et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. // J Clin Oncol.-1996.-V. 14.-N. l.-P. 7−17.
- Kirkwood J.M., Resnick G.D., Cole B.F. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. // Semin Oncol. -1997. -V. 24. -N. 1. -Suppl 4. -P. 16−23.
- Kirkwood J.M., Ibrahim J.G., Sondak V.K. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. // J Clin Oncol. -2000. -V. 18. -N. 12. -P. 2444−58.
- Kirkwood J.M., Manola J., Ibrahim J. et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. // Clin Cancer Res. -2004. -V. 10. -N. 5.-P. 1670−7.
- Kleeberg U.R., Engel E., Brocker E.B. et al. Effect of Toremifene in patients with metastatic melanoma: a phase II study of the EORTC Melanoma Cooperative Group. // Melanoma Res. -1993. —V. 3. -N. 2. -P. 123−6.
- KIop W.M., Vrouenraets B.C., van Geel B.N. et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.// J Am Coll Surg. -1996. -V. 182. -N. 6. -P. 467−72.
- Koh H.K., Sober A.J., Day C.L. et al. Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. // J Clin Oncol. -1986. -V. 4. -N. 8. -P. 1238−44.
- Kokoschka E.M., Trautinger F., Knobler R.M. et al. Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b. // J Invest Dermatol. -1990. -V. 95 -N. 6. -Supp 1. -P. 193−197
- Konjevic G., Jovic V., Radulovic S. et al. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferonalpha. //Neoplasma. -2001. -V. 48. -N. 3. -P. 175−81.
- Koopal S.A., Tiebosch A.T., Daryanani D. et al. Extra nodal growth as a prognostic factor in malignant melanoma. // Eur J Surg Oncol. -2005. -V. 31. -N. 1. -P. 88−94.
- Kostinas J.E., Leone L.A., Cuttner J. et al. Procarbazine vinblastine and actinoinycin D in stage III and IV melanoma with or without methanol-extracted residue of Bacillus Calmette-Guerin. // Cancer Treat Rep. -1979. -V. 63. -N. 2. -P. 197−200.
- Krag D.N., Weaver D.L., Alex J.C., Fairbank J.T. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. // Surg Oncol. -1993. -V. 2. -N. 6. -P. 335−9.
- Krag D.N., Meijer S.J., Weaver D.L. et al. Minimal-access surgery for staging of malignant melanoma. // Arch Surg. -1995. -V. 130. -N. 6. -P. 654−8.
- Kraut E.H., Walker M.J., Staubus A. et al. Phase II trial of topotecan in malignant melanoma. // Cancer Invest. -1997. -V. 15. -N. 4. -P. 318−20.
- Kretschmer L., Lautenschlager C., Preusser K.P. et al. Axillary recurrence after lymph node excision in malignant melanoma. // Langenbecks Arch Chir. -1993. -V. 378. -N. I. -P. 4−11.
- Kretschmer L. s Helmbold P., Emmert S., Marsch W.C. Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma. // Hautarzt. -2002. -V. 53. -N. 8. -P. 536−41.
- Kretschmer L., Beckmann I., Thorns K.M. et al. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. // Eur J Cancer. -2005. -V. 41. -N. 4. -P. 531−8.
- Kroon B.B., Nieweg O.E. Management of malignant melanoma. // Ann Chir Gynaecol. -2000. -V. 89. -N. 3. -P. 242−50.
- Lacal P.M., Failla C.M., Pagani E. et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. // J Invest Dermatol. -2000. —V. 115. -N. 6. -P. 1000−7.
- Lakhani S., Selby P., Bliss J.M. et al. Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. // Br J Cancer. -1990. -V. 61. -N. 2. -P. 3304.
- Lambe T., Leung J.C., Bouriez-Jones T. et al. CD4 T Cell-Dependent Autoimmunity against a Melanocyte Neoantigen Induces Spontaneous Vitiligo and Depends upon Fas-Fas Ligand Interactions. // J Immunol. -2006. -V. 177. -N. 5. -P. 3055−62.
- Landi M.T., Kanetsky P.A., Tsang S. et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. // J Natl Cancer Inst. -2005. -V. 97. -N. 13. -P. 998−1007.
- Lang PG. Current concepts in tiie management of patients with melanoma. // Am J Clin Dermatol. -2002. -V. 3. -N. 6. -P. 401−26.
- Larkin J.M., Hughes S.A., Beirne D.A. et al. A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. II Br J Cancer. -2007. -V. 96. -N. l.-P. 44−8.
- Lasithiotakis K.G., Leiter U., Gorkievicz R. et al. The incidence and mortality of cutaneous melanoma in southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. // Cancer.-2006.-V. 107.-N. 6.-P. 1331−1339
- Lattanzi S.C., Tosteson T., Chertoff J. ct al. Dacarbazine, cisplatin and carmustinc, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. // Melanoma Res. -1995. -V. 5. -N. 5. -P. 3659.
- Lee S.M., Thatcher N., Dougal M., Margison G.P. Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on 06-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. II Br J Cancer. -1993. -V. 67. -N. 2. -P. 216−21.
- Lee S.M., Margison G.P., Woodcock A. A., Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. // Br J Cancer. -1993. -V. 67. -N. 6. -P. 1356−60.
- Leger-Ravet M.B., Mathiot C., Portier A. et al. Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2. // Cancer Immunol Immunother. -1994.-V. 39. -N. l.-P. 53−8.
- Legha S.S.Current therapy for malignant melanoma. // Semin Oncol. -1989. -V. 16. -N. 1 SuppI l.-P. 34−44.
- Legha S.S., Ring S., Papadopoulos N. et al. A phase II trial of taxol in metastatic melanoma. // Cancer. -1990. -V. 65. -N. 11. -P. 2478−81.
- Legha S.S., Gianan M.A., Plager C. et al. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. II Cancer. -1996. -V. 77. -N. l.-P. 89−96.
- Legha S.S. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. // Semin Oncol. -1997. -V. 24. -N. 1. -Suppl 4. -P. 3943.
- Legha S.S., Ring S., Eton O. et al. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. // Cancer J Sci Am. -1997. -V. 3 -Suppl l.-P. 9−15.
- Lejeune FJ. Phase III adjuvant studies in operable malignant melanoma (review). II Anticancer Res. -1987. -V. 7. -N. 4B. -P. 701−5.
- Lejeune F., Lienard D., Eggermont A. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. // J Infus Chemother. -1995. -V. 5. -N. 2. -P. 73−81.
- Lens M.B., Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. // J Clin Oncol. -2002. -V. 20. -N. 7. -P. 1818−25.
- Leong S.P., Kashani-Sabet M., Desmond R. A. et al. Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. // World J Surg. -2005. -V. 29. -N. 6. -P. 683−91.
- Lewis K.D., Gibbs P., O’Day S. et al. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. // Cancer invest. -2005. -V. 23.-N. 4. -P. 303−8.
- Lewis M. G., Copeman P. W. // Brit. Med. J. -1972. -V. 2. -P. 47−48.
- Li G., Tang L., Zhou X. et al. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. // Melanoma Res. -1998. -V. 8. -N. 1. -P. 17−23.
- Lindner P., Thompson J.F., De Wilt J.H. et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. // Eur J Surg Oncol. -2004. -V. 30, -N. 4. -P. 433−9.
- Lingam M.K., Mackie R.M., McKay A.J. Intraoperative identification of sentinel lymph node in patients with malignant melanoma. // Br J Cancer. -1997. -V. 75. -N. 1. -P. 1505−8.
- Little J.W. Melanoma: etiology, treatment, and dental implications. // Gen Dent. -2006. -V, 54.-N. 1.-P. 61−66.
- Liu Y., Hong L., Wakamatsu K. et al. Comparison of structural and chemical properties of black and red human hair melanosomes. // Photochem Photobiol. -2005. -V. 81. -N. 1. -P. 135−44.
- Livingston P.O., Wong G.Y., Adluri S. et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. // J Clin Oncol. -1994. -V. 12.-N. 5.-P. 1036−44.
- Lock-Andersen J, Rossing N, Drzewiecki KT. Preoperative cutaneous lymphoscintigraphy in malignant melanoma. // Cancer. -1989. -V. 63. -N. 1. -P. 77−82.
- Lock-Andersen J., Hastrup N.C., Drzewiecki K.T. The metastasizing thin cutaneous melanoma. Case report. // Scand J Plast Reconstr Surg Hand Surg. -1989. -V. 23. -N. 2. -P. 153−5.
- Lopez M., Perno C.F., Papaldo P. et al. Phase II study of epirubicin in advanced malignant melanoma. // Invest New Drugs. -1984. -V. 2. -N. 3. -P. 315−7.
- Losckley R.M., Killen N., Leonardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. // Cell. -2001. -V. 104. -P. 487−501.
- Lotem M., Shiloni E., Pappo I. et al. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. // Br J Cancer. 2004. -V. 90. -N. 4. -P. 773−80.
- Loutfi A., Shakr A., Jerry M. et al. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. H Clin Invest Med. -1987. -v. 10. -N. 4. -P. 3258.
- Luikart S.D., Kennealey G.T., Kirkwood J.M. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. // J Clin Oncol. -1984.-V. 2.-N.3.-P. 164−8
- Ma S., Egyhazi S., Martenhed G. et al. Analysis of 0(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. // Melanoma Res. -2002. -V. 12. -N. 4. -P. 335−42.
- Maccauro M., Villano C., Aliberti G. et al. Lymphoscintigraphy with intraoperative gamma probe sentinel node detection: clinical impact in patients with head and neck melanomas. // Q J Nucl Med Mol Imaging. -2005. -V. 49. -N. 3. -P. 245−51.
- Mainwaring P.N., Atkinson H., Chang J. et al. Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma. // Eur J Cancer. -1997. -V. 33. -N. 9. -P. 1388−92.
- Maker A. V., Phan G.Q., Attia P. et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. // Ann Surg Oncol. -2005.-V. 12.-N. 12.-P. 1005−16.
- Manelis G, Shasha SM, Manelis J, Suprun H, Robinson E. Spontaneous regression of malignant melanoma. // Oncology. -1978. -V. 35. -N. 2. -P. 83−6.
- Margolin K.A., Doroshow J.H., Akman S.A. et al. Phase II trial of cisplatin and alphainterferon in advanced malignant melanoma. // J Clin Oncol. -1992. -V. 10. -N. 10. -P. 1574−8.
- Margolin K.A., Liu P.Y., Flaherty L.E. et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. // J Clin Oncol. -1998. -V. 16. -N. 2. -P. 664−9.
- Markovic S., Suman V.J., Dalton R.J. et al. Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma. // Am J Clin Oncol. -2002. -V. 25. -N. 6. -P. 552−6.
- Markowitz J.S., Cosimi L.A., Carey R.W. et al. Prognosis after initial recurrence of cutaneous melanoma. // Arch Surg. -1991. -V. 126. -N. 6. -P. 703−7.
- Masback A., Westerdahl J., Ingvar C. et al. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations. // Cancer. -1997.-V. 79. -N.2.-P. 275−83.
- McClay E.F., Albright K.D., Jones J.A. et al. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. // Int J Cancer. -1993. -V. 55. -N. 6. -P. 1018−22.
- Mc Clay E.F., Mc Clay M.E., Albright K.D. et al. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation. II Cancer. -1993. -V. 72. -N. 6.-P. 1914−8.
- McClay E.F., McClay M.E. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? U J Clin Oncol. -1994. -V. 12. -N. 3. -P. 617−26.
- McClay E.F., McClay M.E., Jones J.A. et al. A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. // Cancer. -1997. -V. 79. -N. 5. -P. 1037−43.
- McClay E.F., McClay M.E., Monroe L. et al. The effect of tamoxifen and cispiatin on the disease-free and overall survival of patients with high risk malignant melanoma. // Br J Cancer. -2000. -V. 83. -N. l.-P. 16−21.
- McClay E.F., McClay M.T., Monroe L. et al. A phase II study of high dose tamoxifen and weekly cispiatin in patients with metastatic melanoma. // Melanoma Res. -2001. -V. 11. -N. 3. -P. 309−13.
- McKinnon J.G., Starritt E.C., Scolyer R.A. et al. Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick. // Ann Surg. -2005. -V. 241. -N. 2.-P. 326−33.
- Merimsky O., Inbar M., Shiloni E. et al. Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine—a preliminary report. // Mol Biother. -1990. -V. 2. -N. 4. -P. 208−10.
- Middleton M.R., Grob J.J., Aaronson N. et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. // J Clin Oncol. -2000.-V. 18.-N. l.-P. 158−66.
- Middleton M.R., Lorigan P., Owen J. et al. A randomized phase III study comparing dacarbazine, BCNU, cispiatin and tamoxifen with dacarbazine and interferon in advanced melanoma. // Br J Cancer. -2000. -V. 82. -N. 6. -P. 1158−62.
- Mikhail G.R., Gorsulowsky D.C. Spontaneous regression of metastatic malignant melanoma. // J Dermatol Surg Oncol. -1986. -V. 12. -N. 5. -P. 497−500.
- Milling S.W., Silvers W.K., Sai T., Mintz B. Decline in MHC class I expression with increasing thickness of cutaneous melanomas in standard-strain transgenic mouse models. // Melanoma Res. -2002.-V. 12.-N. 3.-P. 221−30.
- Minor D.R., Madland M.T., Kashani-Sabet M. et al. A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity. // Cancer Biother Radiopharm. -2005. -v. 20. -N. 5. -P. 479−86.
- Mogii J.S., Ritchie J., Smith SB. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. // J Med Genet. -2005. -V. 42. -N. 7. -P. 583−7.
- Molinari A, Calcabrini A, Meschini S, Stringaro A, Del Bufalo D, Cianfriglia M, Arancia G. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. // Int J Cancer. -1998. -V. 75. -N. 6. -P. 885−93.
- Molinari A., Toccacieli L., Calcabrini A. et al. Induction of P-glycoprotein expression on the plasma membrane of human melanoma cells. // Anticancer Res. -2000. -V. 20. -N. 4. -P. 2691−6.
- Molinari A., Calcabrini A., Meschini S. et al. What is the relationship between P-glycoprotein and adhesion molecule expression in melanoma cells? // Melanoma Res. -2002. -V. 12. -N. 2. -P. 109−14.
- Molinari A., Stringaro A., Gentile M. et al. Invasive properties of multidrug resistant human melanoma cells. // ltal J Anat Embryol. -2005. -V. 110.-N. 2 SuppI l.-P. 135−41.
- Moral A., Lafuente M.J., Lafuente A. et al. MMM Group. Multidisciplinary Malignant Melanoma Group. The use erythrocyte glutathione as a predictive marker for malignant melanoma. // Anticancer Res. -2000. -V. 20. -N. 6C.-P. 4757−60.
- Mortimer J.E., Schulman S., MacDonald J.S. et al. High-dose cispiatin in disseminated melanoma: a comparison of two schedules. // Cancer Chemother Pharmacol. -1990. -V. 25. -N. 5. -P. 373−6.
- Morton D.L., Wen D.R., Wong J.H. et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. // Arch Surg. -1992. -V. 127. -N. 4. -P. 392−9.
- Morton D.L., Cochran A.J., Thompson J.F. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. // Ann Surg. -2005. -V. 242. -N. 3. -P. 302−11.
- Moschos S.J., Kirkwood J.M., Konstantinopoulos P.A. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. // J Clin Oncol. -2004. -V. 22. -N. 1. -P. 11−4.
- Mraz-Gemhard S., Sagebiel R.W., Kashani-Sabet M. et al. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. // Arch Dermatol. -1998. -V. 134.-N. 8.-P. :983−7.
- Mughal T.I., Thomas M.R., Robinson W.A. Role of recombinant alpha-interferon in the treatment of advanced cutaneous malignant melanoma. // Oncology. -1991. -V. 48. -N. 5. -P. 365−8.
- Muhonen T., Hahka-Kemppinen M., Pakkala S., Pyrhonen S. Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma. // J Immunother. -1994.-V. 15.-N. 1.-P. 67−73.
- Mulder N.H., van der Graaf W.T., Willemse P.H. et al. Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. // Br J Cancer. -1994. v. 70. -N. 4. -P. 681−3.
- Naglieri E., Procacci A., Galetta D. et al. Cisplatin, interleukin-2, interferon-alpha and tamoxifen in metastatic melanoma. A phase II study. // J Chemother. -1999. -V. 11. -N. 2. -P. 150−5.
- Nathanson L., Schoenfeld D., Regelson W. et al. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. // Cancer. -1979. -V. 43. -N. 5. -P. 1630−5.
- Nathanson L., Meelu M.A., Losada R. Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin. // Cancer. -1994. -V. 73. -N. 1. -P. 98−102.
- Nathanson L., Garrison M. Megestrol melanoma study. // World J Surg. -1995. -V. 19. -N. 3. -P. 337−42.
- Naysmith L., Waterston K., Ha T. et al. Quantitative measures of the effect of the melanocortin 1 receptor on human pigmentary status. // J Invest Dermatol. -2004. -V. 122. -N. 2. -P. 423−8.
- Nelimark R.A., Peterson B.A., Vosika G.J., Conroy J.A. Vindesine lor metastatic malignant melanoma. A phase II trial. // Am J Clin Oncol. -1983. -V. 6. -N. 5. -P. 561−4.
- Neuber K., Eidam B. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival. // Onkologie. -2006. -V. 29. -N. 8−9. -P. 361−5.
- Newburger A.E., Weinstein G. Cell proliferation patterns in human malignant melanoma, in vivo. // Cancer. -1980. -V. 46. -N. 2. -P. 308−13.
- Newton RA, Smit SE, Barnes CC, Pedley J, Parsons PG, Sturm RA. Activation of the cAMP pathway by variant human MC1R alleles expressed in HEK and in melanoma cells. // Peptides. -2005. -V. 26. -N. 10.-P. 1818−24.
- No authors listed. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group. // Cancer. 1989. -V. 63.-N. 9.-P. 1676−80.
- Noorda E.M., Vrouenraets B.C., Nieweg O.E. et al. Isolated limb perfusion for unresectable melanoma of the extremities. // Arch Surg. -2004. -V. 139. -N. 11. -P. 1237−42.
- Norman J. Jr., Cruse W., Ruas E. et al. The expanding role of lymphoscintigraphy in the management of cutaneous melanoma. First Place Winner: Conrad Jobst award. // Am Surg. -1989. -V. 55. -N. 12. -P. 689−94.
- O’Brien C.J., Gianoutsos M.P., Morgan M.J. Neck dissection for cutaneous malignant melanoma. // World J Surg. -1992. -V. 16. -N. 2. -P. 222−6.
- O’Connnel J., Bennett M.W., Sullivan G.C. et al. The Fas counterattack: cancer as a site of immune privilege. // Immunol. Today. -1999. -V. 20. -P. 46−52.
- O’Connor T.P., Labandter H.P., Hiles R.W., Bodenham D.C. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma. // Br J Plast Surg. -1978. —V. 31. -N. 4. -P. 317−22.
- Odujinrin O., Goldberg D., Doroshow J. et al. Treatment of metastatic malignant melanoma with trimetrexate: a phase II study. // Med Pediatr Oncol. -1990. -V. 18. -N. 1. -P. 49−52.
- Okamoto I., Pirc-Danoewinata H., Ackermann J. et al. Deletions of the region 17p 11−13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridization. // Br J Cancer. -1999.-V. 79.-N. l.-P. 131−7.
- Ou-Yang H., Stamatas G., Kollias N. Spectral responses of melanin to ultraviolet A irradiation. // J Invest Dermatol. -2004. -V. 122. -N. 2. -P. 492−6.
- Oyarbide-Valencia K., van den Boorn J.G., Denman C.J. Therapeutic implications of autoimmune vitiligo T cells. // Autoimmun Rev. -2006. -V. 5. -N. 7. -P. 486−92.
- Pack G. The problem of malignant melanoma. // Proc. 2b Nat. Cancer Confer. -1954. -N. 1.-P. 54−70
- Pagani E, Falcinelli S, Pepponi R. et al. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and 06-methylguanine-DNA methyltransferase activity. // Int J Oncol. -2007. -V. 30.-N 2.-P. 443−51.
- Pak B.J., Chu W., Lu S.J. et al. Lineage-spccific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2. // Cancer Metastasis Rev. -2001. -V. 20. -N. 1−2. -P. 27−32.
- Pakkanen M. Survival rates of patients with malignant melanoma of the skin. // Ann Chir Gynaecol. -1977.-V. 66.-N. l.-P. 31−5.
- Palomares T., Alonso-Varona A., Alvarez A. et al. Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells. // Clin Exp Metastasis. -1997. -V. 15. -N. 3. -P. 329−37.
- Parsad D., Wakamatsu K., Kanwar A.J. et al. Eumelanin and phaeomelanin contents of depigmented and repigmented skin in vitiligo patients. // Br J Dermatol. -2003. -V. 149. -N. 3. -P. 624−6.
- Pectasides D., Alevizakos N., Bafaloukos D. et al. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma. // Am J Clin Oncol. -1994. -V. 17. -N. 1. -P. 55−9.
- Pehamberger H., Soyer H.P., Steiner A. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. // J Clin Oncol. -1998.-V. 16.-N.4.-P. 1425−9.
- Pellegrini A.E. Regressed primary malignant melanoma with regional metastases. // Arch Dermatol. -1980. -V. 116. -N. 5. -P. 585−6.
- Petit T., Borel C., Rixe O., Avril M.F. et al. Complete remission seven years after treatment for metastatic malignant melanoma. // Cancer. -1996. -V. 77. -N. 5. -P. 900−2.
- Phan G.Q., Attia P., Steinberg S.M. et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. //J Clin Oncol. -2001. -V. 19. -N. 15. -P. 3477−82.
- Philip P. A., Carmichael J., Tonkin K. et al. A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. // Eur J Cancer. -1994. -V. 30A. -N. 7. -P. 1027−9.
- Pirard D., Heenen M., Melot C., Vereecken P. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. // Dermatology. -2004. -V. 208. -N. 1. -P. 43−8.
- Poelman M., van der Velde-Zimmermann D., van Doom LJ. et al. The detection of melanoma metastases in sentinel nodes by polymerase chain reaction. //Ned Tijdschr Geneeskd. -1998. -V. 142. -N. 16. -P. 905−8.
- Poste G., Greig R. The experimental and clinical implications of cellular heterogeneity in malignant tumors. // J Cancer Res Clin Oncol. -1983. -V. 106. -N. 3. -P. 159−70.
- Presant C.A., Bartolucci A.A., Balch C., Troner M. A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma. // Cancer. -1982. -V. 49.-N. 7.-P. 1355−7.
- Proebstle T.M., Fuchs T., Scheibenbogen C. et al. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients. // Melanoma Res. -1998. -V. 8. -N. 6. -P. 557−63.
- Punt C.J., van Herpen C.M., Jansen R.L. et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. // Br J Cancer. -1997. -V. 76. -N. 2. -P. 266−9.
- Punt C.J., Eggermont A.M. Adjuvant interferon-alpha for melanoma revisited: news from old and new studies. // Ann Oncol. -2001. -v. 12. -N. 12. -P. 1663−6.
- Pyrhonen S., Kouri M., Holsti L.R., Cantell K. Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma. // Oncology. -1992. -V. 49. -N. 1. -P. 22−6.
- Pyrhonen S., Hahka-Kemppinen M., Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. // J Clin Oncol. -1992. -V. 10. -N. 12. -P. 1919−26.
- Quintela I., Vizoso F., Serra C. Immunohistochemical study of pepsinogen C expression in cutaneous malignant melanoma: association with clinicopathological parameters. // lnt J Biol Markers. -2001. — V. 16.-N.4.-P. 240−4.
- Rampen F.H., Menzel S., Rumke P. Satellite and in-transit (SIT) metastases from melanoma are more predominant in females than in males. // Anticancer Res. -1987. -V. 7. -N. 3. -P. 429−31.
- Rao R.D., Holtan S.G., Ingle J.N. et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. // Cancer. -2006. -V. 106. -N. 2. -P. 375−82.
- Rayner C.R.The results of node resection for clinically enlarged lymph nodes in malignant melanoma. // Br J Plast Surg. -1981. -V. 34. -N. 2. -P. 152−6.
- Redman B.G., Flaherty L., Chou T.H. et al. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy. //J Immunother. -1991. -V. 10. -N. 2. -P. 147−51.
- Rees J.L. The genetics of sun sensitivity in humans. // Am J Hum Genet. -2004. -V. 75. -N. 5.-P. 739−51.
- Reimer T., Herrnring C., Koczan D. et al. FasL: Fas ratio a prognostic factor in breast carcinomas. Cancer Res. -2000. -V. 60. -P. 822−828.
- Reintgen D., Becker J., Seigler H.F. Experimental trials of immunotherapy for malignant melanoma. // Semin Surg Oncol. -1991. -V. 7. -N. 4. -P. 192−8.
- Reintgen D., Saba H. Chemotherapy for stage 4 melanoma: a three-year experience with cisplatin, DTIC, BCNU, and tamoxifen. // Semin Surg Oncol. -1993. -V. 9. -N. 3. -P. 251−5.
- Reintgen D., Cruse C.W., Wells K. et al. The orderly progression of melanoma nodal metastases. // Ann Surg. -1994. -V. 220. -N. 6. -P. 759−67.
- Retsas S., Newton K.A., Westbury G. Vindesine as a single agent in the treatment of advanced malignant melanoma. // Cancer Chemother Pharmacol. -1979. -V. 2. -N. 4. -P. 257−60.
- Reu F.J., Bae S.I., Cherkassky L. et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. // J Clin Oncol. -2006. -V. 24. -N. 2. -P. 37 719.
- Richard J., Bleicher, Richard Essner, Leland J. Foshag et al. Role of Sentinel Lymphadenectomy in Thin Invasive Cutaneous Melanomas. II Journal of Clinical Oncology, -2003. —V. 21. — N. 7.-P. 1326−1331.
- Richards J.M. Sequential chemoimmunotherapy for metastatic melanoma. // Semin Oncol. -1991. -V. 18. -N. 5. -Suppl 7. -P. 91−5.
- Richards J.M., Mehta N., Ramming K., Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. // J Clin Oncol. -1992. -V. 10. -N. 8. -P. 1338−43.
- Richards J.M., Gale D., Mehta N., Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. // J Clin Oncol. -1999. -V. 17. -N. 2.-P. 651−7.
- Richard M.A., Grob J.J., Zarrour H. et al. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. // Melanoma Res. -1998. -V. 8. -N. 2. -P. 1704.
- Richard M.A., Grob J.J., Avril M.F. et al. Delay in diagnosis and melanoma prognosis. Part II. The role of doctors. // Int. J. Cancer. -2000. -V. 89. -N. 3. -P. 280−285.
- Riley P. A. Melanogenesis and melanoma. // Pigment Cell Res. -2003. -V. 16. -N. 5. -P.548.52.
- Ringborg U., Rudenstam C.M., Hansson J. et al. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. // Med Oncol Tumor Pharmacother. -1989. -V. 6. -N. 4. -P. 285−9.
- Ringborg U., Jungnelius U., Hansson J., Strander H. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase 1−11 trial. // Am J Clin Oncol. -1990. -V. 13. -N. 3. -P. 214−7.
- Rixe O., Borel C., Paraiso D. et al. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. // Melanoma Res. -1995. -V. 5.-N. 6.-P. 419−24.
- Robert M.E., Wen D.R., Cochran A.J. Pathological evaluation of the regional lymph nodes in malignant melanoma. // Semin Diagn Pathol. -1993. -V. 10. -N. 1. -P. 102−15.
- Roka F., Kittler H., Cauzig P. Sentinel node status in melanoma patients is not predicitive for overall survival upon multivariate analysis. // Br J Cancer. -2005. -V. 92. -N. 4. -P. 662−7.
- Romanini A., Manca G., Pellegrino D. et al. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome. // Ann Oncol. -2005. -V. 16. -N. 11. -P. 1832−40.
- Romieu C., Pujol H. Chemotherapy of malignant melanomas during extracorporeal circulation. // Ann Chir Plast. -1962. -N. 7. -P. 159−62.
- Rosenberg S.A., White D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. // J Immunother Emphasis Tumor Immunol. -1996. -V. 19. -N. 1. -P. 814.
- Roses D.F., Harris M.N., Gumport S.L. Surgical management for malignant melanoma of the trunk. // Arch Surg. -1981. -V. 116. -N. 3. -P. 315−7.
- Roses D.F., Harris M.N., Gumport S.L. et al. Regional lymph node dissection for malignant melanoma of the extremities. // Surgery. -1981. -V. 89. -N. 6. -P. 654−9.
- Roses D.F., Harris M.N., Hidalgo D. et al. Primary melanoma thickness correlated with regional lymph node metastases. //Arch Surg. -1982. -V. 117 -N. 7. -P. 921−3.
- Roses D.F., Provet J. A., Harris M.N. et al. Prognosis of patients with pathologic stage II cutaneous malignant melanoma. //Ann Surg. -1985. -V. 201. -N. 1. -P. 103−7.
- Rouas-Freiss N., Paul P., Dausset J., Carosella E.D. HLA-G promotes immune tolerance. // J Biol Regul Homeost Agents. // 2000. -V. 14. -N. 2. -P. 93−8.
- Rouvier E., LucianiM.F., Golstein P. Fas involvement in Ca (2+)-independent Tcell-mediated cytotoxicity. J. Exp. Med. -1993. -V. 177. -P 195−200.
- Rouzaud F.M., Kadekaro A.L., Abdel-Malek Z.A., Hearing V.J. MC1R and the response of melanocytes to ultraviolet radiation. // Mutat Res. -2005. -V. 571. -N. 1−2 -P. 133−52.
- Rouzaud F, Hearing VJ. Regulatory elements of the melanocortin 1 receptor. // Peptides. -2005.-V. 26.-N. 10.-P. 1858−70
- Rouas-Freiss N, Paul P, Dausset J, Carosella ED. HLA-G promotes immune tolerance. // J Biol Regul Homeost Agents. -2000. -V. 14. -N. 2. -P. 93−8.
- Rudolf Z., Strojan P. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma. // Neoplasma. -1996. -V. 43. -N. 2. -P. 93−7.
- Rumke P., Kleeberg U.R., MacKie R.M. et al. Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group. // Melanoma Res. -1992. -V. 2. -N. 3. -P. 153−6.
- Runger T.M., Emmert S., Schadendorf D. et al. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. // J Invest Dermatol. -2000. -V. 114. -N. 1. -P. 34−9.
- Rybak S.M., Sanovich E., Hollingshead M.G. et al. Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res. -2003. -V. 63. -N. 11.-P. 2812−9.
- Sabel M.S., Sondak V.K. Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma?// Drugs. -2003. -V. 63.-N. II.-P. 1053−8.
- Sabel M.S., Griffith K., Sondak V.K. et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. //J Am Coll Surg. -2005. -V. 201. -N. 1. -P. 37−47.
- Saleh F.H., Crotty K.A., Hersey P., Menzies S.W. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. // Int J Cancer. -2001. -V. 94.-N. 4.-P. 551−7.
- Salter J., MacLennan K., Bridgewater J.A. et al. The histological and immunohistochemical changes in the skin of patients with melanoma who develop changes in skin pigmentation following immunotherapy. // Melanoma Res. -1995. -V. 5. -N. 4. -P. 267−71.
- Samokhvalov A., Hong L., Liu Y. et al. Oxidation potentials of human eumelanosomes and pheomelanosomes. // Photochem Photobiol. -2005. -V. 81. -N. 1. -P. 145−8.
- Sanchez-Mas J., Sanchez-Laorden B.L., Guillo L.A. et al. The melanocortin-1 receptor carboxyl terminal pentapeptide is essential for MC1R function and expression on the cell surface. // Peptides. -2005. -V. 26. -N. 10. -P. 1848−57.
- Saunders M.P., Salisbury A.J., O’Byrne K.J. et al. A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine. // Anticancer Res. -1997. -V. 17. -N. 6D. -P. 4677−80.
- Sauroja 1., Smeds J., Vlaykova T. et al. Analysis of G (l)/S checkpoint regulators in metastatic melanoma. // Genes Chromosomes Cancer. -2000. -V. 28. -N. 4. -P. 404−14.
- Schadendorf D., Makki A., Stahr C. et al. Membrane transport proteins associated with drug resistance expressed in human melanoma. // Am J Pathol. -1995. -V. 147. -N. 6. -P. 1545−52.
- Schallreuter K.U., Wenzel E., Brassow F.W. et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. // Cancer Chemother Pharmacol. -1991. -V. 29. -N. I. -P. 85−7.
- Schallreuter K.U., Wood J.M., Mensing H., Breitbart EAV. Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine. // Cancer Chemother Pharmacol. -1991. -V. 29. —N. 2. -P. 167−71.
- Schallreuter K.U., Wood J.M. New aspects in the pathophysiology of cutaneous melanoma: a review of the role of thioproteins and the effect of nitrosoureas. // Melanoma Res. -1991. -V. 1. -N. 3. -P. 15 967.
- Schuchter LM. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? //J Clin Oncol. -2004. -V. 22. -N. 1. -P. 7−10.
- Schultz M.Z., Buzaid A.C., Poo W.J. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. // Melanoma Res. -1997. -V. 7. -N. 2.-P. 147−51.
- Seeber A., Binder M., Steiner A. et al. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. // Eur J Cancer. -1998. -V. 34. -N. 13. -P. 2129−31.
- Seigler H.F., Lucas V.S. Jr., Pickett N.J., Huang A.T. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. // Cancer. -1980. -V. 46. -N. 11. -P. 2346−8.
- SelzerE., Wacheck V., Kodym R. et al. Erythropoietin receptor expression in human melanoma cells. // Melanoma Res. -2000. -V. 10. -N. 5. -P. 421−6.
- Serrone L., Zeuli M., Sega F.M., Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. // J Exp Clin Canccr Res. -2000. -V. 19. -N. 1. -P. 21−34.
- Sessa C., Aamdal S., Wolff I. et al. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group. // Ann Oncol. -1994. -V. 5.-N.5.-P. 471−2.
- Shresta S., Pham C.T., Thomas D.A. et al. How do cytotoxic lymphocytes kill their targets? // Cuit. Opin. Immunol.-1998.-V. 10.-P. 581−587.
- Silver H.K., Ibrahim E.M., Evers J.A. et al. Adjuvant BCG immunotherapy for stage I and II malignant melanoma. // Can Med Assoc J. -1983. -V. 128. -N. 11. -P. 1291−5.
- Slavik M., Liu P.Y., Kraut E.H. et al. Evaluation of merbarone (NSC 336 628) in disseminated malignant melanoma. A Southwest Oncology Group study. // Invest New Drugs. -1995. -V. 13. -N. 2. —N. 143−7.
- Slingluff C.L. Jr., Stidham K.R., Ricci W.M.et al. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients.// Ann Surg. -1994. -V. 219. -N. 2. -P. 12 030.
- Smolle J. Biological basis of metastasis formation. // Hautarzt. -1992. -V. 43. -N. 2. -P. 5564.
- Soengas M.S., Capodieci P., Polsky D. et al. lnactivation of the apoptosis effector Apaf-1 in malignant melanoma. //Nature. -2001.-V. 409. -N. 6817. -P. 207−11.
- Sondak V.K., Liu P.Y., Flaherty L.E. et al. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study. // Cancer J Sci Am. -1999. -V. 5.-N. 1. -P. 41−7.
- Soong S.J., Harrison R.A., McCarthy W.H. et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. // J Surg Oncol. -1998. -V. 67. -N. 4. -P 228−33.
- Soubrane C., Mouawad R., Antoine E.C. et al. A comparative study of fas and Fas-ligand expression during melanoma progression. // British Journal of Dermatology-2000. -V 143. -P 307−312.
- Southwick H.W. Malignant melanoma. Role of node dissection reappraised. // Cancer. -1976. -V. 37. -N. 1.-P. 202−5.
- Spatz A. The role of the pathologist in management of patients with melanoma. ESO Red Square Seminar® // Skin Melanoma yesterday and today. -Moscow. -2005. -P. 179−194.
- Stables G.I., Doherty V.R., MacKie R.M. Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma. // Br J Dermatol. -1992. -V. 127.-N. 5.-P. 505−8.
- Stanley P. L. Leong, MD, FACS Paradigm of Metastasis for Melanoma and Breast Cancer Based on the Sentinel Lymph Node Experience 10.1245/ASO. // Annals of Surgical Oncology. -2004. -N. 11. -P. 192S-197.
- Stegmaier O.C.J. // Invest. Derm. -1959. -V. 32. -P. 413−421.
- Stehlin J.S. Jr., Giovanella B.C., de Ipolyi P.D., Anderson R.F. Results of eleven years' experience with heated perfusion for melanoma of the extremities. // Cancer Res. -1979. -V. 39. -N. 6 Pt 2. -P. 2255−7.
- Stein M.E., Bernstein Z., Tsalic M. et al. Chemoinununohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study. // Am J Clin Oncol. -2002. -V. 25. -N. 5. -P. 460−3.
- Stewart L.E., Tyler D.S., Vollmer R.T. The importance of total number of sentinel lymph nodes in patients with stage N0 cutaneous melanoma. // Am J Clin Pathol. -2005. -V. 124. -N. 1. -P. 77−82.
- Streit M., Detmar M. Angiogenesis, Iymphangiogenesis, and melanoma metastasis. II Oncogene. -2003. -V. 22. -N. 20. -P. 3172−9.
- Sturm R.A. Skin colour and skin cancer MC1R, the genetic link. // Melanoma Res. -2002. -V. 12.-N. 5.-P. 405−16.
- Suda T., Nagata S. Purification and characterization of Fas-ligand that induces apoptosis. // J. Exp. Med. -1994. -V. 179. -P. 873−879.
- Sugarbaker E.V., McBride C.M. Survival and regional disease control after isolationperfusion for invasive stage I melanoma of the extremities. // Cancer. -1976. -V. 37. -N. 1. -P. 188−98.
- Sugarbaker E.V., McBride C.M. Melanoma of the trunk: the results of surgical excision and anatomic guidelines for predicting nodal metastasis. // Surgery. -1976. -V. 80. -N. 1. -P. 22−30.
- Takahashi T. A study of the photo lightening mechanism of red hair with visible and ultraviolet light: comparison with blond hair. Hi Cosmet Sci. -2005. -V. 56. -N. 1. -P. 47−56.
- Takeuchi S., Zhang W., Wakamatsu K. et al. Melanin acts as a potent UVB photosensitizer to cause an atypical mode of cell death in murine skin. // Proc Natl Acad Sci USA. -2004. -V. 101. -N. 42. -P. 15 076−81.
- Tamm 1., Grimme H., Bergen E. ey al. Dacarbazine and interferon alpha for stage IV malignant melanoma. // Oncology. -1997. -V. 54. -N. 4. -P. 270−4.
- Tang L., Tron V.A., Reed J.C. et al. Expression of apoptosis regulators in cutaneous malignant melanoma. // Clin Cancer Res. -1998. -V. 4. -N. 8. -P. 1865−71.
- Thatcher D., Lind M., Morgenstern G. et al. High-dose, double alkylating agent chemotherapy with DT1C, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. II Cancer. -1989. -V. 63. -N. 7. -P. 1296−302.
- Thatcher N., Wagstaff J., Mene A. et al. Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma. // Eur J Cancer Clin Oncol.-1986.-V. 22.-N. 8.-P. 1009−14.
- Thatcher N., Dazzi H., Mellor M. et al. Recombinant interIeukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study. // Br J Cancer. -1990. -V. 61. -N. 4. -P. 61 821.
- Thomas P., Dalle E., Revillon B. et al. Cutaneous effects in hormonal contraception. // NPN Med.-1985.-V. 5.-N. 81.-P. 19−24.
- Thompson JA, Gold PJ, Fefer A. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Scmin Oncol. -1997. -V.24. -N. 1. -Suppl. 4. -P. 44−8.
- Thompson J.A., Gold P.J., Markowitz D.R. et al. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. // Cancer J Sci Am. -1997. -V. 3. -Suppl 1. -P. 29−34.
- Thompson J.F., Uren R.F. Lymphatic mapping and sentinel node biopsy for melanoma. // Expert Rev Anticancer Ther. -2001. -V. 1. -N. 3. -P. 446−52.
- Tiffet O., Perrot J.L., Soler C. et al. Recherche des metastases ganglioneires des melanomes malins apres isolement du ganglion sentinelle. // Ann. Chir. -2000. -V. 125. -N. 1. -P. 32−39.
- Tillman D.M., Aitchison T., Watt D.C. et al. Stage II melanoma in the west of Scotland, 1976−1985: prognostic factors for survival. // Eur J Cancer. -1991. -V. 27. -N. 7. -P. 870−6.
- Tranum B.L., Dixon D., Quagliana J. et al. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study. // Cancer Treat Rep. -1987. -V. 71. -N. 6. -P. 643−4.
- Traut B.C., Klas C., Peters A.M. et al. Monoclonal antibodi-mediate tumor regression by induction of apoptosis. Scince. -1989. -V 245. -P 301−305.
- Ugurel S., Reinhold U., Tilgen W. HLA-G in melanoma: A new strategy to escape from immunosurveillance? // Onkologie. -2002. -V. 25. -N. 2. -P. 129−34.
- Uren R.F., Howman-Giles R.B., Shaw H.M. et al. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. // J Nucl Med. -1993. -V. 34. -N. 9. -P. 1435−40.
- Uren R.F., Howman-Giles R., Thompson J.F., McCarthy W.H. Exclusive lymphatic drainage from a melanoma on the back to intraabdominal lymph nodes. // Clin Nucl Med. -1998. -V. 23. -N. 2. -P. 71−3.
- Vaishampayan U., Abrams J., Darrah D. et al. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. // Clin Cancer Res. -2002. -V. 8. -N. 12. -P. 3696−701.
- Verma S., Quirt I., McCready D. et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. // Cancer. -2006. -V. 106. -N. 7. -P. 1431−42.
- Veronesi U., Cascinelli N., Morabito A. et al. Prognosis of stage I melanoma of the skin. Who collaborating centers for evaluation of methods of diagnosis and treatment of melanoma. // Int. J. Cancer. -1980. -V. 26. -N. 6. -P. 733−739.
- Veronesi U., Adamus J., Aubert C. et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. //N Engl J Med. -1982. -V. 307. -N. 15. -P. 913−6.
- Veronesi U., Adamus J., Bandiera D.C. et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. // Cancer. -1982. -V. 49. -N. 11. -P. 2420−30.
- Verschraegen C.F., Kleeberg U.R., Mulder J. et al. Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group. // Cancer. -1988. -V. 62. -N. 6. -P. 1061−5.
- Verschraegen C.F., Legha S.S., Hersh E.M. et al. Phase II study of vindesine and dacarbazine with or without non-spccific stimulation of the immune system in patients with metastatic melanoma. // Eur J Cancer. -1993. -V. 29A. -N. 5. -P. 708−11.
- Viard I Wehrli P., Bullani R., Schneider P. et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. // Science. -1998. -V. 282. -P. 490−3.
- Vilella R., Benitez D., Mila J. et al. Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine. // Int J Cancer. -2003. -V. 106.-N. 4.-P. 626−31.
- Vlaykova ., Talve L., Hahka-Kemppinen M. et al. Immunohistoehemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response. // Oncology. -2002. -V. 62.-N. 3.-P. 259−68.
- Vuoristo M.S., Grohn P., Kellokumpu-Lehtinen P. et al. Intermittent interferon and polychemotherapy in metastatic melanoma. //J Cancer Res Clin Oncol. -1995. -V. 121. -N. 3. -P. 175−80.
- Walker L., Schalch H., King D.M. et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. // Melanoma Res. -2005. -V. 15. -N. 5. -P. 453−9.
- Walker P.R., Saas P., Dietrich P.Y. Tumor expression of Fas ligand (CD95L) and consequenses. Curr. Opin. Immunol. -1998. -V. 10. -P. 564−572.
- Wang X., Heller R., VanVoorhis N. et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. // Ann Surg. -1994. -V. 220. -N. 6. -P. 768−74.
- Wayte D. M., Helwig E.B. // Cancer (Philad). -1968. -V. 21. -P. 215−225.
- Weinstein G.D., Mooney K.M. Cell proliferation kinetics in the human hair root. // J Invest Dermatol. -1980. -V. 74. -N. 1. -P. 43−6.
- Wheatley K., Ives N. Adjuvant interferon for melanoma. // Ann Oncol. -2002. -V. 13. -N. 8. -P. 1319−20.
- Wheatley K., Ives N., Hancock B. et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. // Cancer Treat Rev. -2003. -29. -N. 4. -P. 241−52.
- Whitaker D.K., Sinclair W. Melanoma Advisory Board. Guideline on the management of melanoma. // S Air Med J. -2004. -V. 94. -N. 8 Pt 3. -P. 699−707.
- Whittington R., Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. // Drugs. -1993. -V. 46. -N. 3. -P. 446−514.
- Wiernik PH, Einzig AL Taxol in malignant melanoma. // J Natl Cancer Inst Monogr. -1993. -V. 15.-P. 185−7.
- Willers J., Urosevic M., Laine E. et al. Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression. // J Invest Dermatol.-2001. -V. 117.-N. 6.-P. 1498−504.
- Wolf M., Bauder-Wust U., Haberkom U. et al. Alkylating benzamides with melanoma cytotoxicity: role of melanin, tyrosinase, intracellular pl l and DNA interaction. // Melanoma Res. -2005. -V. 15.-N. 5.-P. 383−91.
- Wright N.A., Al-Dewachi H.S., Appleton D.R., Watson A.J. Cell population kinetics in the rat jejunal crypt. // Cell Tissue Kinet. -1975. -V. 8. -N. 4. -P. 361−8.622. www.afanas.ru/privivki/bcg.htm
- Wyman K., Atkins M.B., Prieto V., Eton O. et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. // Cancer. -2006. -V. 106. —N. 9.-P. 2005−11.
- Yonehara S., Ishii A., Yonehara M. Acell-killing monoclonal antibody (anti-Fas) to cell surface antigen co-downregulated with the receptor tumor necrosis factor. // J. Exp. Med. -1989. -V 169. -P 1747−1756.
- York R.M., Foltz A.T. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.Cancer. // 1988. -V. 61. -N. 11. -P. 2183−6.
- Young A.M., Marsden J., Goodman A. et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. // Clin Oncol (R Coll Radiol). -2001. -V. 13. -N. 6. -P. 458−65.
- Zimmermann T., Buhr J., Kelm C., Padberg W. Results of elective lymph node excision in melanoma of the trunk. // Zentralbl Chir. -1996. -V. 121. -N. 6. -P. 478−82.
- Zogakis T.G., Essner R., Wang H.J. et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. //Arch Surg. -2005. -V. 140. -N. 9. -P. 865−71.